Jun 26 2024 |
et al., BioImpacts, doi:10.34172/bi.29952 | Effectiveness of dolutegravir in moderate severity COVID-19 patients: A single-center, randomized, double-blind, placebo-controlled trial |
| 202% higher mortality (p=0.49) and 5% lower need for oxygen therapy (p=1). RCT 93 hospitalized patients with moderate COVID-19 showing no significant difference in clinical outcomes with dolutegravir treatment compared to placebo. | ||
Apr 13 2023 |
et al., AIDS, doi:10.1097/QAD.0000000000003577 | No association between use of tenofovir disoproxil fumarate, etravirine, or integrase-strand transfer inhibitors and acquisition or severe outcomes of SARS-CoV-2 infection in people with HIV in the Netherlands |
| 14% higher combined mortality/hospitalization (p=0.54) and 20% more cases (p=0.75). Analysis of two Dutch cohorts with HIV showing no association between tenofovir disoproxil fumarate (TDF), etravirine (ETR), or integrase-strand transfer inhibitors (INSTIs) use and either the risk of incident SARS-CoV-2 infection or seve.. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.